![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Once-per-week or Every-two-week Dosing Regimen is More Efficacious for the TLR7 Agonist JNJ-64794964 (JNJ-4964) to Induce an Anti-hepatitis B Virus (HBV) Effect
and HBV-specific Immune Responses in AAV-HBV Mice
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Florence Herschke1, Chris Li2,*, Ren Zhu2, Qinglin Han2, Qun Wu2, Qing Lu2, Tse-I Lin3,*, An De Creus1
1Janssen Pharmaceutica NV, Beerse, Belgium; 2Asia Pacific Centre of Excellence of Translational Science, Shanghai, China; 3Janssen South San Francisco, CA, USA
*No longer with Janssen
![0918201](../images/091820/091820-8/0918201.gif)
![0918202](../images/091820/091820-8/0918202.gif)
![0918203](../images/091820/091820-8/0918203.gif)
![0918204](../images/091820/091820-8/0918204.gif)
![0918205](../images/091820/091820-8/0918205.gif)
![0918206](../images/091820/091820-8/0918206.gif)
![0918207](../images/091820/091820-8/0918207.gif)
![0918208](../images/091820/091820-8/0918208.gif)
![0918209](../images/091820/091820-8/0918209.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|